The Health Care M&A Monthly: To The Winners Go The Spoils… Boston Scientific’s $27 Billion Bid for Guidant Trumps Johnson & Johnson’s While Abbott Laboratories Lands Itself a Strong Vascular Business
Email Editor Knowing when to hold ‘em and knowing when to fold ‘em are useful skills in more games than just poker. The bidding war for Guidant Corporation (NYSE: GDT), raging over the past two months, has finally come to an end with Guidant’s board accepting Boston...The Health Care M&A Monthly: Health Care M&A Results for The Fourth Quarter of 2005
Email Editor The fourth quarter of 2005 saw a total of 221 mergers and acquisitions in 13 sectors of the health care industry. This represents a 13% decrease from the 253 deals in the previous quarter, but a 2% increase over the 217 deals in the year-ago quarter,...The Health Care M&A Monthly: The Year in Health Care M&A, 2005
Email Editor By all accounts, the M&A market for 2005 was a good one, a very good one. Based on figures at hand, a total of 964 deals were announced in the 13 sectors of the health care industry we cover. This figure represents a 10% increase over the 874 deals...The Health Care M&A Monthly: One Target, Two Buyers
We have recently seen a spate of deals with buyer and seller plodding through due diligence toward completion only to be caught off guard by an interloper intent on snagging the target for himself. A new offer is made, generally with better terms, that bumps the...The Health Care M&A Monthly: JNJ Cuts Offer By 15 Percent, Will Buy Guidant For $21.5 Billion
Last December we showcased 2004’s largest domestic transaction: Johnson & Johnson’s (NYSE: JNJ) purchase of medical device maker Guidant Corporation (NYSE: GDT) in a deal worth $25.4 billion. During the 11 months since its announcement, this deal has unfolded—and...Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
